Disease Progression Increases the Risk of Skeletal-Related Events in Patients With Bone Metastases From Castration-Resistant Prostate Cancer, Lung Cancer, or Other Solid Tumors

REFERENCES

• Coleman, R.E. Metastatic bone disease: clinical features, pathophysiology, and treatment strategies. Cancer Treat Rev 2001, 27(3), 165–176.
   PubMed Web of Science ®Google Scholar
• Saad, F.; Lipton, A. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol 2007, 34(6 Suppl 4), S17–S23.
   PubMed Web of Science ®Google Scholar
• Weinfurt, K.P.; Castel, L.D.; Li, Y.; Timbie, J.W.; Glendenning, G.A.; Schulman, K.A. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 2004, 42(2), 164–175.
   PubMed Web of Science ®Google Scholar
• Weinfurt, K.P.; Li, Y.; Castel, L.D.; Saad, F.; Timbie, J.W.; Glendenning, G.A.; Schulman, K.A. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005, 16(4), 579–584.
   PubMed Web of Science ®Google Scholar
• Saad, F.; Lipton, A.; Cook, R.; Chen, Y.-M.; Smith, M.; Coleman, R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110(8), 1860–1867.
   PubMed Web of Science ®Google Scholar
• Halabi, S.; Vogelzang, N.J.; Kornblith, A.B.; Ou, S.-S.; Kantoff, P.W.; Dawson, N.A.; Small, E.J. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 2008, 26(15), 2544–2549.
   PubMed Web of Science ®Google Scholar
• Hirsh, V.; Tchekmedyian, N.S.; Rosen, L.S.; Zheng, M.; Hei, Y.-J. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 2004, 6(3), 170–174.
   PubMedGoogle Scholar
• Rosen, L.S.; Gordon, D.; Tchekmedyian, N.S.; Yanagihara, R.; Hirsh, V.; Krzakowski, M.; Pawlicki, M.; De Souza, P.; Zheng, M.; Urbanowitz, G.; Reitsma, D.; Seaman, J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004, 100(12), 2613–2621.
   PubMed Web of Science ®Google Scholar
• Rosen, L.S.; Gordon, D.; Tchekmedyian, S.; Yanagihara, R.; Hirsh, V.; Krzakowski, M.; Pawlicki, M.; de Souza, P.; Zheng, M.; Urbanowitz, G.; Reitsma, D.; Seaman, J.J. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003, 21(16), 3150–3157.
   PubMed Web of Science ®Google Scholar
• Saad, F.; Gleason, D.M.; Murray, R.; Tchekmedyian, S.; Venner, P.; Lacombe, L.; Chin, J.L.; Vinholes, J.J.; Goas, J.A.; Chen, B. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94(19), 1458–1468.
   PubMed Web of Science ®Google Scholar
• Saad, F.; Gleason, D.M.; Murray, R.; Tchekmedyian, S.; Venner, P.; Lacombe, L.; Chin, J.L.; Vinholes, J.J.; Goas, J.A.; Zheng, M. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96(11), 879–882.
   PubMed Web of Science ®Google Scholar
• Kohno, N.; Aogi, K.; Minami, H.; Nakamura, S.; Asaga, T.; Iino, Y.; Watanabe, T.; Goessl, C.; Ohashi, Y.; Takashima, S. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005, 23(15), 3314–3321.
   PubMed Web of Science ®Google Scholar
• Rosen, L.S.; Gordon, D.; Kaminski, M.; Howell, A.; Belch, A.; Mackey, J.; Apffelstaedt, J.; Hussein, M.A.; Coleman, R.E.; Reitsma, D.J.; Chen, B.-L.; Seaman, J.J. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98(8), 1735–1744.
   PubMed Web of Science ®Google Scholar
• Aapro, M.; Abrahamsson, P.A.; Body, J.J.; Coleman, R.E.; Colomer, R.; Costa, L.; Crino, L.; Dirix, L.; Gnant, M.; Gralow, J.; Hadji, P.; Hortobagyi, G.N.; Jonat, W.; Lipton, A.; Monnier, A.; Paterson, A.H.G.; Rizzoli, R.; Saad, F.; Thurlimann, B. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008, 19(3), 420–432.
   PubMed Web of Science ®Google Scholar
• Smith, M.R.; Cook, R.J.; Coleman, R.; Brown, J.; Lipton, A.; Major, P.; Hei, Y.J.; Saad, F. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 2007, 70(2), 315–319.
   PubMed Web of Science ®Google Scholar
• Andersen, P.K.; Gill, R.D. Cox's regression model for counting processes: a large sample study. Ann Stat 1982, 10(4), 1100–1120.
   Web of Science ®Google Scholar
• Brown, J.E.; Cook, R.J.; Major, P.; Lipton, A.; Saad, F.; Smith, M.; Lee, K.-A.; Zheng, M.; Hei, Y.J.; Coleman, R.E. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005, 97(1), 59–69.
   PubMed Web of Science ®Google Scholar
• Cook, R.J.; Coleman, R.; Brown, J.; Lipton, A.; Major, P.; Hei, Y.J.; Saad, F.; Smith, M.R. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006, 12(11 pt 1), 3361–3367.
   PubMed Web of Science ®Google Scholar
• Lipton, A.; Cook, R.; Saad, F.; Major, P.; Garnero, P.; Terpos, E.; Brown, J.E.; Coleman, R.E. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008, 113(1), 193–201.
   PubMed Web of Science ®Google Scholar
• Hirsh, V.; Major, P.P.; Lipton, A.; Cook, R.J.; Langer, C.J.; Smith, M.R.; Brown, J.E.; Coleman, R.E. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008, 3(3), 228–236.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals. Zometa® (Zoledronic Acid) Injection [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008.
   Google Scholar